Business
Director Dealings
Director Dealings.
About this update from Genflow Biosciences Plc
[{"type":"text","content":"\n\n \nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n \n28 March 2025\n \nGenflow Biosciences Plc \n \nDirector's Dealing\n \nGenflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (\"Genflow\" or \"the Company\") the only longevity company listed in Europe, is pleased to announce that it has been notified that Dr. Eric Leire, CEO of the Company, has today purchased 2,100,000 ordinary shares in the Company at a price of 1.15 pence each on the open market.\n \nDetails of the transaction are set out below:\n \n\n\n\n\nName\n\n\nDr. Eric Leire\n\n\n\n\n\n\nPosition\n\n\nChief Executive Officer\n\n\n\n\nDate of Purchase\n\n\n27 March 2025\n\n\n\n\nNumber of Ordinary Shares Purchased\n\n\n2,100,000\n\n\n\n\nPrice per Ordinary Share\n\n\n1.15p\n\n\n\n\nTotal Consideration\n\n\n£24,150\n\n\n\n\nNature of Transaction\n\n\nMarket purchase\n\n\n\n\nTotal Shareholding Following the Transaction\n\n\n126,514,999\n \n\n\n\n\nInterest in Ordinary Shares (percentage)\n\n\n36.18%\n\n\n\n\n \nNOTIFICATION AND PUBLIC DISCLOSURE OF A TRANSACTION BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM\n \nThe following disclosure is made in accordance with the requirements of the UK Market Abuse Regulation and provides details in relation to the purchase of Ordinary Shares by a Director:\n \n\n\n\n\n1.\n\n\nDetails of the person discharging managerial responsibilities / person closely associated\n\n\n\n\na)\n\n\nName\n\n\nEric Leire\n \n\n\n\n\n2.\n\n\nReason for the Notification\n\n\n\n\na)\n\n\nPosition/status\n\n\nPDMR\n \n \n\n\n\n\nb)\n\n\nInitial notification / Amendment\n\n\nInitial notification\n \n \n\n\n\n\n3.\n\n\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\n\n\n\n\na)\n\n\nName\n\n\nGenflow Biosciences Plc\n \n \n\n\n\n\nb)\n\n\nLEI\n\n\n213800HVOFXRXVEGDN62\n \n \n\n\n\n\n4.\...